June 23, 2021—RapidPulse, Inc. announced the closing of a $15 million Series A financing that the company plans to use to advance its RapidPulse cyclic aspiration system through expanded clinical evaluation and build out its platform of proprieta…
Penumbra’s Red 62 Reperfusion Catheter Cleared by FDA
June 23, 2021—Penumbra, Inc. announced FDA 510(k) clearance and commercial availability of the Red 62 reperfusion catheter, an addition to the Penumbra system for mechanical thrombectomy.
According to the company, Red 62 is designed to navigat…
Sensome’s Clotild AI-Powered Stroke Guidewire Receives FDA Breakthrough Device Designation
June 21, 2021—Sensome announced that it has been granted a Breakthrough Device designation by FDA for its Clotild smart guidewire system, which is designed to use artificial intelligence (AI) to improve the treatment of ischemic stroke patients.
…
First patient treated in the BeGraft FEVAR study aimed at providing evidence for on-label use
On 19 March, the first patient was included in the BeGraft fenestrated endovascular aneurysm repair (FEVAR) study investigating the Bentley BeGraft peripheral balloon expandable covered stent in complex aortic aneurysms. The patient was referred for FEVAR with a 6cm juxtarenal abdominal aortic aneurysm, explained the coordinating investigator and study lead, Eric Verhoeven (General Hospital Nuremberg, […]
The post First patient treated in the BeGraft FEVAR study aimed at providing evidence for on-label use appeared first on Vascular News.
Sectoral Asset Management makes US$9 million investment into Cagent Vascular
Cagent Vascular recently announced the investment of US$9 million by Sectoral Asset Management. Along with the investment, Marc-Andre Marcotte has joined the board of directors. The proceeds will be used to accelerate the commercialisation and scaling of manufacturing for the Serranator below-the-knee (BTK) product. Further uses of proceeds include expanding the product offering to include […]
The post Sectoral Asset Management makes US$9 million investment into Cagent Vascular appeared first on Vascular News.
Basement membrane collagen IV deficiency promotes abdominal aortic aneurysm formation
Cagent Vascular Receives Investment to Support Commercialization of Serranator BTK Catheter
June 17, 2021—Cagent Vascular Inc. announced an investment of $9 million by Sectoral Asset Management, which Cagent will use to accelerate the commercialization and scaling of manufacturing for its Serranator below-the-knee (BTK) percutaneous tra…
Large study shows continued and quickening decline in AAA mortality
According to a new, population-based analysis, abdominal aortic aneurysm (AAA) mortality has continued to decline and “at a faster rate than ever” in the second decade of the 21st century. Authors C Y Maximilian Png (Massachusetts General Hospital, Boston, USA), Edward Choke (Sengkang General Hospital, Singapore), and colleagues attribute this continued and accelerating decline to […]
The post Large study shows continued and quickening decline in AAA mortality appeared first on Vascular News.
Femoropopliteal bypass shows reintervention benefit over endovascular therapy for advanced premature PAD
Femoropopliteal bypass is associated with decreased reinterventions at one year compared to endovascular therapy in patients with advanced premature peripheral arterial disease (PAD). This is the primary conclusion of Tanner I Kim (Yale School of Medicine, New Haven, USA) and colleagues, writing in an article recently published online in the Journal of Vascular Surgery. The […]
The post Femoropopliteal bypass shows reintervention benefit over endovascular therapy for advanced premature PAD appeared first on Vascular News.
Updated Summary-Level Analysis of Paclitaxel-Coated Devices Shows No Evidence of Increased All-Cause Mortality Risk
June 15, 2021—In an updated systematic review and meta-analysis of randomized controlled trials (RCTs) of paclitaxel-coated device (PCD) use in patients with occlusive femoropopliteal disease, Dinh et al found no increased risk of all-cause morta…